Navigation Links
ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
Date:9/21/2010

lin resistance.

CCX140 is chemically distinct from all other known antagonists of CCR2 and works by blocking the monocyte/macrophage infiltration that occurs during inflammation and thus is designed to provide selective treatment of the disease without compromising other immune functions.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, completed a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission over the course of the trial.  Phase III clinical trials of Traficet-EN are expected to initiate in the fourth quarter 2010.  In addition, CCX025, also a CCR9 antagonist, has successfully completed a Phase I clinical program. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; and CCX168, a C5aR antagonist, in Phase I clinical development. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is private
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. Spherix Reports Second Quarter Earnings
11. Tapestry Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Somewhere between dropping ... health was forgotten. But Audicus , a next-generation ... better this new year. Hearing loss is ... aging population, though it is often unaddressed. Forty-eight million ... has a hearing aid, mainly due to price. Hearing ...
(Date:12/19/2014)... 18, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year 2015 results on Thursday, January 22, 2015, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:12/19/2014)... has witnessed robust development with the growth pace keeping at ... In 2012, the size of China ... worldwide soaring to 16.3%. It is projected that ... rate by around 20% in the upcoming years and that ... An integrated membrane industrial system has taken shape ...
Breaking Medicine Technology:Audicus Will Help People Resolve to Hear Better in 2015 2ResMed To Announce Second Quarter 2015 Results 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
(Date:12/19/2014)... illness-causing E. coli bacteria were found on nearly one-quarter ... new study. Researchers checked cilantro, basil and parsley ... Los Angeles and Orange counties in California, and in ... 24 percent were positive for E. coli. One sample ... Both types of bacteria can cause sometimes serious or ...
(Date:12/19/2014)... The cost of cancer treatment can cause financial stress ... Researchers examined data from 1,000 people in the United ... cancer. Of those patients, almost 900 had finished their ... advanced cancer. Nearly half of the patients said ... was linked with a poorer health-related quality of life. ...
(Date:12/19/2014)... Diet Doc strives to continue to provide ... weight loss by combining scientific fast weight loss ... company understand that remaining committed to a diet can ... and sugars from the diet can cause patients to ... loss goals. , For this reason, Diet Doc ...
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Hospital in Franklin, Ind. The top executive search firm ... placed more than 900 healthcare executives into organizations. ... service hospital providing care to the residents of Johnson ...
(Date:12/19/2014)... Mobile Spa, has announced they now have a Virtual ... into a utopia for the Long Island community where the ... Tour showcases the beauty of the Spa On Wheels which ... The Virtual Tour shows viewers each of the rooms in ... Marla Kaplan-Pelle, Director states " It's hard to imagine that ...
Breaking Medicine News(10 mins):Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3
... greatly increases the risk of heart diseases as an adult, according ... heart disease is not how much you weigh now, but how ... with a low birth weight are roughly twice as susceptible to ... an epidemologist at the University of Southampton, and a team at ...
... The right side of the brain helps people recognise ... from the Beth Israel Deaconess Medical Center in Boston ... ,The study joins a growing body of evidence ... in self-awareness.// Studies of self-awareness may provide unique insights ...
... who do not express their requests feel less satisfied with their ... not tell a patient everything on his mind. One may feel ... she may seem rushed, or it may be that the relationship ... as it could be.// ,Researchers at the University of ...
... differences in disease patterns in different mammals - and it ... genes with our primate cousins - yet they rarely get ... dogs do not suffer from high blood pressure, even when ... Professor of Comparative Medicine at the University of Houston and ...
... tool to the field of medicine. An interactive video ... treatment. The days when doctors told you what treatment ... participate in the decision-making process.// But sometimes this is ... new research comes up all the time. ...
... or sleep apnoea has the potential to alter voice characteristics. ... stops many times during the night - is to remodel ... is that the uvula - a flap of tissue at ... ,If the uvula is trimmed - in an operation called ...
Cached Medicine News:Health News:The right is responsible 2
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Pefakit in-TDT Calibrators and Controls...
PT-HS with Calcium - 2 ml...
Medicine Products: